PTC Therapeutics (PTCT - Free Report) shares rallied 5.8% in the last trading session to close at $41.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% gain over the past four weeks.
The stock rallied after the company reported robust preliminary net revenues as well as net product revenues for full year 2022 at the J.P. Morgan Healthcare Conference on Jan 9. The company also provided strong guidance for total revenues for full year 2023 at the conference. This is also a positive.
This biopharmaceutical company is expected to post quarterly loss of $1.61 per share in its upcoming report, which represents a year-over-year change of +20.7%. Revenues are expected to be $195.3 million, up 18.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For PTC Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PTCT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
PTC Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Esperion Therapeutics (ESPR - Free Report) , closed the last trading session 11% higher at $6.99. Over the past month, ESPR has returned 23.8%.
For Esperion Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +50.9% from what the company reported a year ago. Esperion Therapeutics currently has a Zacks Rank of #3 (Hold).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
PTC Therapeutics (PTCT - Free Report) shares rallied 5.8% in the last trading session to close at $41.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% gain over the past four weeks.
The stock rallied after the company reported robust preliminary net revenues as well as net product revenues for full year 2022 at the J.P. Morgan Healthcare Conference on Jan 9. The company also provided strong guidance for total revenues for full year 2023 at the conference. This is also a positive.
This biopharmaceutical company is expected to post quarterly loss of $1.61 per share in its upcoming report, which represents a year-over-year change of +20.7%. Revenues are expected to be $195.3 million, up 18.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For PTC Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PTCT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
PTC Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Esperion Therapeutics (ESPR - Free Report) , closed the last trading session 11% higher at $6.99. Over the past month, ESPR has returned 23.8%.
For Esperion Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +50.9% from what the company reported a year ago. Esperion Therapeutics currently has a Zacks Rank of #3 (Hold).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PTCT - FREE
Get the latest research report on ESPR - FREE